2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

In patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.

Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis

“…And platinum-based combination therapies are recommended as first-line chemotherapy for patients with advanced NSCLC [4][5][6]. But the adverse reaction and response rate of the medication are still remaining a problem.…”

Les traitements de maintenance dans les cancers bronchiques non à petites cellules métastatiques en 2012

“…Les recommandations internationales pour le traitement des formes métastatiques des CBNPC initialement fondées sur la stratégie du "stop and go" [1] ont récemment évolué en intégrant la "switch" maintenance comme option chez les patients [2]. En effet, avec la stratégie classique, la moitié des patients contrôlés par une bithéra-pie à base de platine voit leur maladie progresser dans les 2 à 3 mois suivant l'arrêt du traitement et près d'un tiers des patients ne reçoit pas de traitement de seconde ligne.…”

Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer

“…Patients received a doublet platinum-based chemotherapy according to the American Society for Clinical Oncology (ASCO) or European Society for Medical Oncology (ESMO) guidelines [3,14], with carboplatin or cisplatin in combination with another third generation agent, with possible addition of bevacizumab. Adequate premedication, including aprepitant for cisplatin-based regimens, was administered before chemotherapy.…”